Prévisions du marché thérapeutique des maladies infectieuses en Asie-Pacifique jusqu’en 2030 – Analyse régionale – par classe de médicaments (antiviraux, antibactériens, antifongiques et autres), indication (VIH, hépatite, tuberculose, grippe, VPH et autres), itinéraire De l\'administration (orale, parentérale, topique et autres) et du canal de distribution (pharmacies hospitalières, pharmacies de détail et autres)

BMIRE00030366 | Pages: 101 | Pharmaceuticals | Jul 2024 | Type: Regional | Status: Published
Le marché thérapeutique des maladies infectieuses en Asie-Pacifique était évalué à 25 904,61 millions de dollars américains en 2022 et devrait atteindre 37 415,07 millions de dollars américains d’ici 2030 ; on estime qu\'il enregistrera un TCAC de 4,7 % de 2022 à 2030.

Les opportunités croissantes dans les pays en développement stimulent le marché thérapeutique des maladies infectieuses en Asie-Pacifique

L\'incidence croissante des maladies infectieuses devrait augmenter le ventes de médicaments thérapeutiques contre les maladies infectieuses dans les pays en développement. L’Asie-Pacifique est devenue une plaque tournante adaptable et conviviale pour les entreprises en raison d’exigences légèrement moindres en matière de données et de réglementations strictes. En outre, les investissements élevés dans la recherche en santé et les sciences de la vie dans les pays émergents jouent un rôle clé dans la promotion des dernières technologies dans les pays en développement, ce qui, à son tour, soutient la tendance au diagnostic et au traitement des maladies infectieuses. Par exemple, l’ONUSIDA appelle à un investissement de 29 milliards de dollars d’ici 2025 pour répondre aux besoins des pays à revenu faible et intermédiaire en matière de riposte au sida. Ainsi, les fabricants cruciaux de produits thérapeutiques contre les maladies infectieuses sur les marchés émergents de la thérapie contre les maladies infectieuses en Inde et en Corée du Sud devraient bénéficier d’opportunités lucratives à l’avenir. Cela est dû à la forte prévalence de maladies infectieuses telles que l\'hépatite, les IAS, le VIH et la grippe ; une large population de patients ; une augmentation du revenu disponible de la population ; améliorer les infrastructures de soins de santé ; et le tourisme médical croissant dans ces pays.

Aperçu du marché thérapeutique des maladies infectieuses en Asie-Pacifique

Le marché thérapeutique des maladies infectieuses en Asie-Pacifique est sous-segmenté en Chine, en Inde, au Japon, en Corée du Sud, en Australie et dans le reste de l\'Asie-Pacifique. L’Asie-Pacifique devrait enregistrer le TCAC le plus rapide au cours de la période de prévision. Le marché dans la région devrait croître en raison de l’augmentation des dépenses de santé mondiales, de l’incidence croissante des maladies chroniques et infectieuses et de l’augmentation de la population gériatrique. Les maladies infectieuses telles que la grippe, l\'hépatite B et la diarrhée infectieuse sont courantes en Chine, tandis que la typhoïde, le paludisme, la jaunisse, la tuberculose et le sida sont courants en Inde. La grippe, l\'hépatite B et la diarrhée infectieuse sont les trois maladies infectieuses courantes en Chine. Comme l\'a déclaré Frontiers Public Health, le pic hivernal de la grippe a coïncidé avec l\'épidémie de COVID-19 dans le pays en 2021. Selon le directeur pays de la Banque mondiale pour la Chine 2020, le pays présente un risque élevé de maladies infectieuses en raison de son population croissante, abondance de la faune, fragmentation de l’habitat et niveaux élevés de production animale. Compte tenu de l\'incidence croissante des maladies infectieuses dans le pays, le Conseil d\'administration de la Banque mondiale a approuvé un prêt de 300 millions de dollars pour le projet de prévention, de préparation et de réponse aux maladies infectieuses émergentes. Cela l’aidera à réduire le risque de zoonoses et d’autres menaces émergentes pour la santé. Ainsi, l’incidence croissante des maladies infectieuses et les mesures prises pour contrôler ces maladies devraient stimuler le marché chinois des traitements contre les maladies infectieuses dans les années à venir.

Revenus et prévisions du marché thérapeutique des maladies infectieuses en Asie-Pacifique jusqu\'en 2030 (millions de dollars américains)

Segmentation du marché thérapeutique des maladies infectieuses en Asie-Pacifique

Le marché thérapeutique des maladies infectieuses en Asie-Pacifique est classé par classe de médicament, indication, voie d’administration, canal de distribution et pays.

En fonction de la classe de médicaments, le marché thérapeutique des maladies infectieuses de la région Asie-Pacifique est segmenté en antiviraux, antibactériens, antifongiques et autres. Le segment des antiviraux détenait la plus grande part de marché en 2022.

En termes d\'indication, le marché thérapeutique des maladies infectieuses de l\'Asie-Pacifique est segmenté en VIH, hépatite, tuberculose, grippe, VPH et autres. Le VIH détenait la plus grande part de marché en 2022.

En fonction de la voie d\'administration, le marché thérapeutique des maladies infectieuses de l\'Asie-Pacifique est segmenté en administration orale, parentérale, topique et autres. Le segment oral détenait la plus grande part de marché en 2022.

En termes de canal de distribution, le marché thérapeutique des maladies infectieuses de la région Asie-Pacifique est segmenté en pharmacies hospitalières, pharmacies de détail et autres. Les pharmacies hospitalières détenaient la plus grande part de marché en 2022.

Par pays, le marché thérapeutique des maladies infectieuses de l\'Asie-Pacifique est segmenté en Chine, au Japon, en Inde, en Australie, en Corée du Sud et dans le reste de l\'Asie-Pacifique. La Chine a dominé la part de marché des produits thérapeutiques contre les maladies infectieuses en Asie-Pacifique en 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc et Shionogi & Co Ltd comptent parmi les principales sociétés opérant sur le marché thérapeutique des maladies infectieuses en Asie-Pacifique.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

4.2 Market Drivers

4.2.1 Rising Prevalence of Infectious Disease

4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics

4.3 Market Restraints

4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects

4.4 Market Opportunities

4.4.1 Growing Opportunities in Developing Nations

4.4.2 Escalating Threat of Antibiotic Resistance

4.5 Future Trends

4.5.1 Rising Number of Product Approvals and Launches

4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis

5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class

6.1 Overview

6.2 Anti-Viral

6.2.1 Overview

6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.3 Anti-bacterial

6.3.1 Overview

6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Anti-fungal

6.4.1 Overview

6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.5 Others

6.5.1 Overview

6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication

7.1 Overview

7.2 HIV

7.2.1 Overview

7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Hepatitis

7.3.1 Overview

7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Tuberculosis

7.4.1 Overview

7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Influenza

7.5.1 Overview

7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.6 HPV

7.6.1 Overview

7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Topical

8.4.1 Overview

8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.5 Others

8.5.1 Overview

8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel

9.1 Overview

9.2 Hospital Pharmacies

9.2.1 Overview

9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Retail Pharmacies

9.3.1 Overview

9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis

10.1 Asia Pacific Infectious Disease Therapeutics Market Overview

10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Overview

10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.4.1 Overview

10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.6.1 Overview

10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration

10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.8.1 Overview

10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration

10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.10.1 Overview

10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.12.1 Overview

10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

11.1 Overview

11.2 Growth Strategies in the Infectious Disease Therapeutics Market

11.3 Inorganic Growth Strategies

11.3.1 Overview

11.4 Organic Growth Strategies

11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Gilead Sciences Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 F. Hoffmann-La Roche Ltd

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Shionogi & Co Ltd

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Bayer AG

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 GSK Plc

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 AbbVie Inc

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Merck & Co Inc

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Astellas Pharma Inc

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

13. Appendix

13.1 About The Insight Partners

List of Tables

Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation

Table 2. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class

Table 3. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication

Table 4. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 5. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 6. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country

Table 7. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 8. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 9. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 10. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 11. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 12. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 13. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 14. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 15. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 16. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 17. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration

Table 18. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 19. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 20. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 21. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration

Table 22. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 23. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 24. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 25. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 26. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market

Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List of Figures

Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country

Figure 2. Impact Analysis of Drivers and Restraints

Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)

Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)

Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)

Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 31. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market

1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc 
7. Merck & Co Inc
8. Pfizer Inc
9. Shionogi & Co Ltd

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific infectious disease therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific infectious disease therapeutics market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440